Rationale for an intraperitoneal gemcitabine chemotherapy treatment for patients with resected pancreatic cancer

Recent Patents on Anti-Cancer Drug Discovery

Volumn 4, Issue 2, 2009, Pages 174-179

  Kamath, Anil ^a   Yoo, Dal ^a   Stuart, Oswald A ^a   Bijelic, Lana ^a   Sugarbaker, Paul H ^a  

^a WASHINGTON CANCER INSTITUTE   (United States)

Author keywords

Chemoradiation; Chemotherapy; European Organization for Research and Treatment of Cancer (EORTC); Morbidity; Mortality; Pancreatic cancer; Randomized trials

Indexed keywords

CAPECITABINE; CISPLATIN; FLUOROURACIL; GEMCITABINE; IRINOTECAN; MITOMYCIN C; OXALIPLATIN; PACLITAXEL; ANTINEOPLASTIC ANTIMETABOLITE; DEOXYCYTIDINE; DRUG DERIVATIVE;

ABDOMINAL PAIN; AREA UNDER THE CURVE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CELLULITIS; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG TOLERABILITY; HUMAN; MONOTHERAPY; MORBIDITY; MORTALITY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEPHROTOXICITY; NEUROPATHY; OVARY CANCER; OVARY CARCINOMA; OVERALL SURVIVAL; PANCREAS CANCER; PANCREAS RESECTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RADIATION DOSE; REVIEW; STEADY STATE; SURVIVAL RATE; THROMBOCYTOPENIA; HYPERTHERMIC THERAPY; INTRAPERITONEAL DRUG ADMINISTRATION; MULTIMODALITY CANCER THERAPY; PANCREAS TUMOR; RANDOMIZED CONTROLLED TRIAL;

ANTIMETABOLITES, ANTINEOPLASTIC; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; HUMANS; HYPERTHERMIA, INDUCED; INJECTIONS, INTRAPERITONEAL; PANCREATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 68949110248     PISSN: 15748928     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489209788452876     Document Type: Review

References (31)

1. Jemal A, Thomas A, Murray T, Thun M. Cancer statistics. CA Cancer J Clin 2002; 52: 23-47.
2. Schneider G, Siveke JT, Eckel F, Schmid RM. Pancreatic cancer: Basic and clinical aspects. Gastroenterology 2005; 128: 1606-1625.
3. Sener SF, Fremgen A, Menck HR, Winchester DP. Pancreatic cancer: A report of treatment and survival trends for 100,313 patients diagnosed from 1985-1995, using the National Cancer Database. J Am Coll Surg 1999; 189: 1-7.
4. Warshaw AL, Fernandez-del Castillo C. Pancreatic carcinoma. N Engl J Med 1992; 326 (7): 455-465.
5. Dedrick RL. Theoretical and experimental bases of intraperitoneal chemotherapy. Semin Oncol 1985; 12(3 Suppl 4): 1-6.
6. Kalser MH, Ellenberg SS. Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg 1985; 120: 899-903.
7. Klinkenbijl J, Jeekel J, Sahmoud T, et al. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: Phase III trial of the EORTC Gastrointestinal Tract Cancer Cooperative Group. Ann Surg 1999; 230: 776-784.
8. Neoptolemos J, Dunn J, Stocken D, et al. Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: A randomized controlled trial. Lancet 2001; 358: 1576-1585.
9. Neoptolemos J, Stocken D, Freiss H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 2004; 350: 1200-1210.
10. Oettle S, Post S, Neuhaus P, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: A randomized controlled trial. JAMA 2007; 297(3): 267-277.
11. Neuhaus P, Riess H, Post S, et al. CONKO-001: Final results of the randomized, prospective, multicenter phase III trial of adjuvant chemotherapy with gemcitabine versus observation in patients with resected pancreatic cancer (PC). J Clin Oncol 2008; 26(May 20 Suppl; abstr LBA4504).
12. Gandhi V. Questions about gemcitabine dose rate: Answered or unanswered? J Clin Oncol 2007; 25(36): 5691-5694.
13. Sabbatini P, Aghajanian C, Leitao M, et al. Intraperitoneal cisplatin with intraperitoneal gemcitabine in patients with epithelial ovarian cancer: Results of a phase I/II Trial. Clin Cancer Res 2004; 10(9): 2962-2967.
14. Pestieau S, Stuart OA, Chang D, et al. Pharmacokinetics of intraperitoneal gemcitabine in a rat model. Tumori 1998; 84: 708-713.
15. Sugarbaker PH, Mora JT, Carmignani P, et al. Update on chemotherapeutic agents utilized for perioperative intraperitoneal chemotherapy. Oncologist 2005; 10(2): 112-122.
16. Gamblin TC, Egorin MJ, Zuhowski EG, et al. Intraperitoneal gemcitabine pharmacokinetics: A pilot and pharmacokinetic study in patients with advanced adenocarcinoma of the pancreas. Cancer Chemother Pharmacol 2007 Nov 27 Epub ahead of print.
17. Armstrong DK, Bundy B, Wenzel L, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. Gynecologic Oncology Group. N Engl J Med 2006; 354: 34-43.
18. Walker JL, Armstrong DK, Huang HQ, et al. Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: A Gynecologic Oncology Group Study. Gynecol Oncol 2006; 100(1): 27-32.
19. National Cancer Institute. Clinical announcement on intraperitoneal chemotherapy in ovarian cancer. Cancer Therapy Evaluation Program. Bethesda (MD): NCI 2006.
20. Burris HA 3rd, Moore M, Anderson J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial. J Clin Oncol 1997; 15: 2403-2413.
21. Berlin JD, Catalano P, Thomas JP, Kugler JW. Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J Clin Oncol 2002; 20(15): 3270-3275.
22. Stathopoulos GP, Syrigos K, Aravantinos G, et al. A multicenter phase III trial comparing irinotecan-gemcitabine (IG) with gemcitabine (G) monotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancer. Br J Cancer 2006; 95(5): 587-592.
23. Heinemann V, Quietzsch D, Gieseler F, Gonnermann M. Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol 2006; 24(24): 3946-3952.
24. Louvet C, Labianca R, Hammel P, et al. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: Results of a GERCOR and GISCAD phase III trial. J Clin Oncol 2005; 23(15): 3509-3516.
25. Heinemann V, Labianca R, Hinke A, Louvet C. Increased survival using platinum analog combined with gemcitabine as compared to single-agent gemcitabine in advanced pancreatic cancer: Pooled analysis of two randomized trials, the GERCOR/GISCAD intergroup study and a German multicenter study. Ann Oncol 2007; 18(10): 1652-1659.
26. Scheithauer W, Schull B, Ulrich-Pur H, Schmid K. Biweekly highdose gemcitabine alone or in combination with capecitabine in patients with metastatic pancreatic adenocarcinoma: A randomized phase II trial. Ann Oncol 2003; 14(1): 97-104.
27. Tuinmann G, Hegewisch-Becker S, Zschaber R, Kehr A. Gemcitabine and mitomycin C in advanced pancreatic cancer: A single-institution experience. Anticancer Drugs 2004; 15(6): 575-579.
28. Sugarbaker PH. An instrument to provide containment of intraoperative intraperitoneal chemotherapy with optimized distribution. J Surg Oncol 2005; 92(2): 142-146.
29. Baldi, G., Bonacchi, D., Innocenti, F., Lorenzi, G., Bitossi, M., Ferruti, P., Ranucci, E., Ricci, A.,Comes, F. M.: WO2008074804 (2008).
30. Szasz, A., Szasz, O.: EP1916013 (2008).
31. Wedge, S. R.: KR20080031029 (2008).